About This Episode
Attorneys Sara Shikhman and Samara Bell navigate the 2026 regulatory shift, tackling the FDA's new proactive enforcement on RF microneedling and compounded drugs. Part of the Business of Aesthetics podcast collection, Episode 258, “Compliance Outlook: RF Microneedling, Compounded Drugs, and the FDA's New Enforcement Priorities,” adds useful context for aesthetic-practice professionals. It gives practice leaders a grounded business lens for evaluating financial, compliance, and risk-related decisions with greater clarity. Listeners can use the conversation to reflect on their current approach, discuss relevant questions with their team, and identify practical next steps.